Recent SEC filings and analyst reports provide a comprehensive overview of Roivant Sciences Ltd. (NASDAQ:ROIV) stock activity and financial performance. Several institutional investors have adjusted their positions in the company, indicating a mix of confidence and strategic realignment.

Credit Industriel ET Commercial initiated a new position, purchasing 150,000 shares valued at $1,774,000. Other institutional investors, including Treasurer of the State of North Carolina, GAMMA Investing LLC, WINTON GROUP Ltd, Covestor Ltd, and PNC Financial Services Group Inc., increased their stakes in Roivant Sciences during the fourth quarter. BlackBarn Capital Partners LP also increased its holdings by 3.1%, making Roivant Sciences its biggest holding, representing 2.7% of its investment portfolio. Substantial increases were also seen from FMR LLC, Vanguard Group Inc., Invesco Ltd., and Geode Capital Management LLC, while Norges Bank initiated a new stake. Currently, institutional investors own 64.76% of the company’s stock.

Roivant Sciences' stock performance shows the stock opened at $10.74 on a particular Thursday and $10.04 on a subsequent Tuesday. The company has a market capitalization of $7.66 billion and $7.16 billion respectively, a P/E ratio of -71.60 and -66.93, and a beta of 1.25. The stock’s fifty-day moving average is approximately $10.33 and $10.32, and its two-hundred-day moving average is $11.15 and $11.16. The fifty-two week range is between $8.73 and $13.06.

The company's recent earnings data, released on February 10th, showed a quarterly earnings per share (EPS) of ($0.20), which beat analysts’ estimates of ($0.24) by $0.04. Roivant Sciences has a negative return on equity of 14.05% and a negative net margin of 119.54%. Current analyst forecasts predict an EPS of -0.92 for the year.

Analyst ratings have been updated recently, with Cantor Fitzgerald upgrading Roivant Sciences to a “strong-buy” rating. HC Wainwright reaffirmed a “buy” rating with a price target of $18.00.

Insider trading activity reveals that COO Eric Venker sold shares in two transactions, one for 315,522 shares at an average price of $11.06 and another for 218,041 shares at an average price of $10.42. CAO Rakhi Kumar also sold 227,500 shares at $10.43. These sales represent significant decreases in their positions. In the last 90 days and last quarter, insiders have sold 1,395,541 and 1,295,541 shares respectively, and insiders currently own 7.90% of the stock.

Roivant Sciences Ltd. operates as a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for inflammation and immunology. They utilize the Vants model to advance biopharmaceutical businesses, discovery-stage companies, and health technology startups.